SCHEMBL654874

SCHEMBL654874

CN1CCN(c2ccc(C(=O)Nc3n[nH]c4cc(C(=O)NC(C)(C)c5ccccc5F)oc34)c([N+](=O)[O-])c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.46
KIT P10721 2/20 0.43
FLT3 P36888 2/20 0.43
ALK Q9UM73 12/20 0.43
INSR P06213 11/20 0.43
IGF1R P08069 7/20 0.42
PLK4 O00444 2/20 0.41
DAPK3 O43293 2/20 0.41
NTRK1 P04629 2/20 0.41
PRKCG P05129 2/20 0.41
ROS1 P08922 2/20 0.41
FER P16591 2/20 0.41
LTK P29376 2/20 0.41
FRK P42685 2/20 0.41
MST1R Q04912 2/20 0.41
PTK2 Q05397 2/20 0.41
TNK2 Q07912 2/20 0.41
NTRK3 Q16288 2/20 0.41
MAP4K5 Q9Y4K4 2/20 0.41
WEE1 P30291 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653322 0.89 ALK (0.54) AURKAKITFLT3ALKINSR
SCHEMBL4082899 0.87 AURKA (0.60) AURKAKITFLT3ALKINSR
SCHEMBL652599 0.86 MEN1 (0.41)
SCHEMBL4093460 0.79 AURKA (0.48) AURKAKITFLT3ALKINSR
SCHEMBL653335 0.77 FADS1 (0.36) AURKAALKINSRIGF1RKDR
SCHEMBL4082088 0.77 SMN1; SMN2 (0.41) ABL1
SCHEMBL4086497 0.77 AURKA (0.71) AURKAKITFLT3ABL1
SCHEMBL4084047 0.76 AURKA (0.42) AURKANTRK1FGFR1FGFR3CDK7
SCHEMBL653354 0.76 RXFP1 (0.38) KIT
SCHEMBL652262 0.76 AURKA (0.54) AURKAKITFLT3ALKINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119641-B2 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-21 US disclosed
EP-2051981-B1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2010-08-25 EP disclosed
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-09-24 US disclosed
EP-2051981-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2009-04-29 EP disclosed
WO-2007138017-A1 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239924-A1 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS IGF1R, CDK1, CDK15 AURKA 5/4885KIT 695/4885FLT3 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.